ES2092539T3 - Uso de derivados de la tiazolidina-4-carboxilato para el tratamiento de enfermedades pulmonares. - Google Patents

Uso de derivados de la tiazolidina-4-carboxilato para el tratamiento de enfermedades pulmonares.

Info

Publication number
ES2092539T3
ES2092539T3 ES91121524T ES91121524T ES2092539T3 ES 2092539 T3 ES2092539 T3 ES 2092539T3 ES 91121524 T ES91121524 T ES 91121524T ES 91121524 T ES91121524 T ES 91121524T ES 2092539 T3 ES2092539 T3 ES 2092539T3
Authority
ES
Spain
Prior art keywords
treatment
thiazolidine
pulmonary diseases
carboxylate derivatives
carboxylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91121524T
Other languages
English (en)
Inventor
Dennis I Goldberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transcend Therapeutics Inc
Original Assignee
Transcend Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24563439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2092539(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transcend Therapeutics Inc filed Critical Transcend Therapeutics Inc
Application granted granted Critical
Publication of ES2092539T3 publication Critical patent/ES2092539T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION ACTUAL PROPORCIONA LA PREPARACION DE UN COMPUESTO UTILIZADO PARA EL TRATAMIENTO DE LAS ENFERMEDADES PULMONARES. MAS ESPECIFICAMENTE, LA INVENCION ACTUAL PROPORCIONA LA PREPARACION DE UN COMPUESTO PARA TRATAR AQUELLAS ENFERMEDADES, TALES COMO EL SINDROME DE RESPIRACION DOLOROSA DE LOS ADULTOS QUE DA COMO RESULTADO AL TENSION DE OXIDACION QUE DAÑA LAS CELULAS DE LOS PULMONES. DE CONFORMIDAD CON LA INVENCION ACTUAL, SE UTILIZA UN SUSTRATO NO CISTEINICO QUE ES UN PRECURSOR PARA LA SINTESIS INTRACELULAR DEL GLUTATIONE, PARA CREAR UN COMPUESTO QUE SE VA A ADMINISTRAR A UN PACIENTE Y QUE AUMENTA LOS NIVELES DE GLUTATIONE INTRACELULAR DE POR LO MENOS AQUELLAS CELULAS DEL PACIENTE CON ENFERMEDADES PULMONARES.
ES91121524T 1991-01-10 1992-01-01 Uso de derivados de la tiazolidina-4-carboxilato para el tratamiento de enfermedades pulmonares. Expired - Lifetime ES2092539T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63927591A 1991-01-10 1991-01-10

Publications (1)

Publication Number Publication Date
ES2092539T3 true ES2092539T3 (es) 1996-12-01

Family

ID=24563439

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91121524T Expired - Lifetime ES2092539T3 (es) 1991-01-10 1992-01-01 Uso de derivados de la tiazolidina-4-carboxilato para el tratamiento de enfermedades pulmonares.

Country Status (10)

Country Link
US (1) US5824693A (es)
EP (2) EP0715853A1 (es)
JP (2) JP2969236B2 (es)
AT (1) ATE144142T1 (es)
AU (2) AU1006492A (es)
CA (1) CA2058793A1 (es)
DE (1) DE69214467T3 (es)
DK (1) DK0494405T3 (es)
ES (1) ES2092539T3 (es)
GR (1) GR3021890T3 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631234A (en) * 1991-04-15 1997-05-20 Teijin Limited Method for treating ischemia-reperfusion tissue injury
FR2763845B1 (fr) 1997-05-30 2003-04-18 Centre Nat Rech Scient Produits anti-cancereux pour le traitement de la mucoviscidose
US6197749B1 (en) 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
EP1004302A3 (en) * 1998-10-29 2003-06-04 Ajinomoto Co., Inc. Immunomodulator
WO2001012166A2 (en) 1999-08-17 2001-02-22 University Of Saskatchewan Technologies Inc. Improved treatment for acute physical insult to the central nervous system
US7179791B2 (en) * 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
KR100478536B1 (ko) * 2002-10-14 2005-03-24 주식회사 에이.비.아이 Ｌ-2-옥소씨아졸리딘-4-카르복실산 또는 그 염을유효성분으로 함유하는 천식 치료용 약제학적 조성물
US20040229815A1 (en) 2003-01-03 2004-11-18 Nagasawa Herbert T. Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
US7781539B2 (en) 2003-02-21 2010-08-24 Metabolix Inc. PHA blends
PT1603987E (pt) 2003-02-21 2011-11-10 Metabolix Inc Composições adesivas pha
JP2007517126A (ja) 2003-12-30 2007-06-28 メタボリックス インコーポレイティッド 増核剤
US20090192227A1 (en) * 2005-08-24 2009-07-30 Rabindra Tirouvanziam N-Acetylcysteine Compositions and Methods for Treating Acute Exacerbations of Inflammatory Lung Disease
CA2620123C (en) * 2005-08-24 2011-11-22 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating and monitoring inflammation and redox imbalance in cystic fibrosis
US7526715B2 (en) 2005-10-17 2009-04-28 Ramot At Tel Aviv University Ltd. Probabilistic error correction in multi-bit-per-cell flash memory
US20070255406A1 (en) * 2006-04-27 2007-11-01 Sdgi Holdings, Inc. Devices, apparatus, and methods for bilateral approach to disc augmentation
CN109054254B (zh) 2012-08-17 2021-02-02 Cj第一制糖株式会社 用于聚合物共混物的生物基橡胶改性剂
WO2014070769A1 (en) 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
US20140234397A1 (en) * 2013-02-15 2014-08-21 Lou Ann Brown Treatment of klebsiella pneumoniae with liposomally formulated glutathione
WO2014194220A1 (en) 2013-05-30 2014-12-04 Metabolix, Inc. Recyclate blends
US11602555B2 (en) 2016-11-17 2023-03-14 Renovion, Inc. Treatment of respiratory tract diseases and infections with ascorbic acid compositions
CN111615395B (zh) 2017-11-17 2024-08-06 莱诺翁股份有限公司 稳定的抗坏血酸组合物及其使用方法
CN113797230A (zh) * 2020-06-12 2021-12-17 上海萨美细胞技术有限公司 无细胞脂肪提取液对肺部疾病的治疗用途
KR20240131358A (ko) 2022-01-04 2024-08-30 레노비온, 아이엔씨. 글루타치온 염을 포함하는 수용액

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2712202A (en) * 1954-06-08 1955-07-05 Univ Alabama Method of treating tree diseases
DE1767335A1 (de) * 1968-04-27 1971-09-02 Bayer Ag Anaesthetikum fuer Tiere
US3755578A (en) * 1969-06-06 1973-08-28 Pfizer Thiazoline and 5,6-dihydro-4h-1,3-thiazine anti-plant-viral agents
DE2141765A1 (de) * 1971-08-20 1973-03-01 Henkel & Cie Gmbh 4-chlor-4-thiazolin-2-one und verfahren zu deren herstellung
FR2296428A1 (fr) * 1975-01-03 1976-07-30 Baignes Ste Radegonde Laiterie Composition de proteines a usage dietetique et therapeutique chez le nourrisson, l'enfant et l'adulte
JPS53119866A (en) * 1977-03-25 1978-10-19 Yoshitomi Pharmaceut Ind Ltd 5-aryloxy-oxazoleakanoic acid derivatives and their preparation
EP0002978B1 (fr) * 1977-12-29 1982-10-06 Synthelabo Dérivés de thiazolidinedione-2,4, leur préparation et leur application en thérapeutique
US4384001A (en) * 1978-12-21 1983-05-17 Gosalvez Mario Treatment of tumors with thiazolidine-4-carboxylic acid
US4338315A (en) * 1979-11-14 1982-07-06 Eli Lilly And Company Antiviral method employing thiazinyl benzimidazole derivatives
US4434158A (en) * 1981-02-11 1984-02-28 Cornell Research Foundation Cysteine delivery system
US4647571A (en) * 1981-02-11 1987-03-03 Cornell Research Foundation Cysteine delivery composition
US4665082A (en) * 1981-02-11 1987-05-12 Cornell Research Foundation Cysteine delivery system
US4335210A (en) * 1981-02-11 1982-06-15 Cornell Research Foundation Method of producing L-cysteine
US4438124A (en) * 1981-02-11 1984-03-20 Cornell Research Foundation, Inc. Cysteine delivery system
JPS57200373A (en) * 1981-06-04 1982-12-08 Taisho Pharmaceut Co Ltd Thiazolidine derivative
US4420479A (en) * 1982-04-08 1983-12-13 Eli Lilly And Company Olefinic benzimidazoles, formulations, and antiviral methods
DE3317000C2 (de) * 1983-05-10 1986-09-25 Gödecke AG, 1000 Berlin 4-Oxo-thiazolidin-2-yliden-acetamid-derivate, Verfahren zu deren Herstellung und deren Verwendung bei der Bekämpfung von durch das Zentralnervensystem bedingten Konvulsionen
US4879370A (en) * 1983-12-02 1989-11-07 Cornell Research Foundation, Inc. Glutathione delivery system
US4752618A (en) * 1984-07-12 1988-06-21 New England Deaconess Hospital Method of minimizing efects of infection through diet
US4647453A (en) * 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
US4710489A (en) * 1985-04-22 1987-12-01 Cornell Research Foundation, Inc. Glutathione delivery system
HU200177B (en) * 1985-06-18 1990-04-28 Biogal Gyogyszergyar Process for producing thiazolidinecarboxylic acids and pharmaceutical compositions comprising such compounds
EP0218900B1 (en) * 1985-09-10 1992-01-22 Research Corporation Technologies, Inc. Osmotic agents for peritoneal dialysis
US4780475A (en) * 1986-02-03 1988-10-25 Cerra Frank B Preparation for the prevention of catabolism
JPS63152325A (ja) * 1986-08-20 1988-06-24 Yamanouchi Pharmaceut Co Ltd 脳虚血症予防治療剤
IT1202426B (it) * 1987-01-26 1989-02-09 Poli Ind Chimica Spa Derivato di acido tiazolidin-4-carbossilico,sua preparazione e composizioni farmaceutiche che lo contengono
US5053387A (en) * 1987-02-20 1991-10-01 Shriners Hospitals For Crippled Children Omega-3 fatty acids in traumatic injury treatment
US4868114A (en) * 1987-08-05 1989-09-19 Regents Of The University Of Minnesota Method for elevating glutathione levels
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituierte Thiazolidindionderivate
US4968671A (en) * 1987-11-26 1990-11-06 Yamanouchi Pharmaceutical Co., Ltd. Therapeutic agents for ischemic heart diseases
US4798835A (en) * 1987-12-02 1989-01-17 Pfizer Inc. dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
ATE110954T1 (de) * 1988-01-29 1994-09-15 Peter H Proctor Haarwachstumanregung mit nitroxyd und anderen radikalen.
IE891173L (en) * 1988-04-18 1989-10-18 Univ Utrecht Composition for promoting hair growth in androgenetic¹alopecia and method thereof
DE3816603A1 (de) * 1988-05-16 1989-11-30 Behringwerke Ag Verwendung des thiazol-derivates tiprotimod zur herstellung eines mittels zur therapie von virusinfektionen
US5055446A (en) * 1988-10-21 1991-10-08 University Of Cincinnati Method to improve survival of patients during sepsis by diet composition
ES2068253T3 (es) * 1988-12-09 1995-04-16 Allergan Inc Uso de acidos tiazolidin-4-carboxilicos sustituidos en la posicion 2 para tratamiento de cataratas.
CA1338682C (en) * 1988-12-23 1996-10-29 Gustavo Bounous Biologically active undenatured whey protein concentrate as food supplement
GB8918709D0 (en) * 1989-08-16 1989-09-27 Unilever Plc Cosmetic composition
US5158883A (en) * 1989-09-13 1992-10-27 Cornell Research Foundation, Inc. Method of using aminoarginine to block nitric oxide formation in vitro
US5028627A (en) * 1989-09-13 1991-07-02 Cornell Research Foundation, Inc. Method of using arginine derivatives to inhibit systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
AU7675891A (en) * 1990-03-28 1991-10-21 Atif M Hussein Methods for protecting against chemotherapy-induced hair loss
US5089268A (en) * 1990-05-02 1992-02-18 Katz David P Egg phosphatide lipid emulsions altered for a specific therapeutic fatty acid composition
US5095027A (en) * 1991-02-28 1992-03-10 Clintec Nutrition Co. Method for treating reperfusion injury employing L-2-oxothiazolidine-4-carboxylic acid
SE9103572D0 (sv) * 1991-11-29 1991-11-29 Astra Ab Organic salts of n,n'-diacetyl cystine
US5214062A (en) * 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
US5208249A (en) * 1992-08-20 1993-05-04 Clintec Nutrition Co. Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate

Also Published As

Publication number Publication date
EP0494405A3 (en) 1992-10-28
EP0494405A2 (en) 1992-07-15
DK0494405T3 (da) 1996-11-18
GR3021890T3 (en) 1997-03-31
AU7912194A (en) 1995-02-16
JP2969236B2 (ja) 1999-11-02
US5824693A (en) 1998-10-20
JPH1053523A (ja) 1998-02-24
AU688803B2 (en) 1998-03-19
DE69214467T2 (de) 1997-04-30
EP0494405B1 (en) 1996-10-16
EP0494405B2 (en) 2000-04-19
CA2058793A1 (en) 1992-07-11
DE69214467T3 (de) 2000-09-28
AU1006492A (en) 1992-07-16
JPH08319242A (ja) 1996-12-03
ATE144142T1 (de) 1996-11-15
EP0715853A1 (en) 1996-06-12
DE69214467D1 (de) 1996-11-21

Similar Documents

Publication Publication Date Title
ES2092539T3 (es) Uso de derivados de la tiazolidina-4-carboxilato para el tratamiento de enfermedades pulmonares.
FI862011A0 (fi) Terapeutiska nukleosider.
ES2113413T3 (es) Derivados antiviricos del acido 2-desoxi-2,3-didehidro alfa-d-neuraminico 4 substituido.
ES2084579T3 (es) Uso de buspirona en la preparacion de una composicion farmaceutica para el tratamiento del abuso del alcohol.
DE69005951D1 (de) Medikamente enthaltend Salmeterol und Fluticason.
ATE75945T1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
ATE276767T1 (de) Ein physiologisch wirksames polypeptid enthaltende pharmazeutische zusammensetzung
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE3883016D1 (de) Komplexe verbindungen aus bioflavonoiden mit phospholipiden, ihre herstellung und verwendung und sie enthaltende pharmazeutische und kosmetische zusammensetzungen.
ES2096215T3 (es) Tucaresol como agente inmunopotenciador.
DE69002718D1 (de) Medikamente.
NO910213D0 (no) Fremgangsmaate for fremstilling av orale legemiddelformer av pimobendan.
SE8400332L (sv) Forening for anvendning som mellanprodukt vid framstellning av lekemedel
ES2141116T3 (es) Utilizacion del peptido natriuretico atrial humano para la obtencion de un medicamento para el tratamiento del sindrome de dificultad respiratoria en el adulto.
DE68901216D1 (de) Feste pharmazeutische zubereitung und verfahren zur herstellung derselben.
DK347289A (da) Terapeutiske forbindelser
ES2060440T3 (es) Derivados de acidos 1,4-dihidropiridin-dicarboxilicos aril-quinolil substituidos, procedimiento para su fabricacion y su uso en medicamentos.
SE8903764D0 (sv) Lung protection agents
ATE2746T1 (de) Piperidinderivate von 4,5-dialkyl-3-hydroxypyrrol-2-carbons[ureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
ITMI911845A1 (it) Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
ATE4808T1 (de) Piperidinderivate von 3-hydroxy-thiophen-2carbons[ureestern,ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
DE3786168D1 (de) Verwendung von para-aminobenzoesaeure zur herstellung eines arzneimittels zur bekaempfung von photoallergien.
DE69131521D1 (de) Alpha-Ergocryptine enthaltende pharmazeutische Zusammensetzungen mit nervenschützender Wirkung

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 494405

Country of ref document: ES